Eli Lilly, Sanofi S.A. deal

The companies formed a joint venture to commercialize in the U.S. Sanofi's oxaliplatin platinum-based cancer compound, which has completed Phase III trials as a first-line therapy in combination with 5-fluorouracil to treat advanced colorectal cancer. The product is marketed in France and is under review in the EU. The companies anticipate making a U.S. regulatory submission in the third quarter. ...